SHL Medical

Based in Switzerland, SHL Medical AG provides innovative drug delivery solutions and services, enhancing patient experiences through advanced technology and design. SHL Medical AG, established in 1989, specializes in the development of drug delivery devices. The company is headquartered in Zug, Switzerland, and operates globally. In December 2022, Athos Service and other investors acquired a minority stake in the company, with EQT reinvesting.

The CEO is Ahmad Shakir, who leads the company towards expanding its market presence. The company specializes in providing advanced assessment solutions that enhance organizational performance and talent management. Their core offerings include a suite of psychometric assessments designed to evaluate candidate suitability, employee engagement, and leadership potential. These assessments are utilized primarily in recruitment processes, employee development initiatives, and succession planning to address critical business challenges such as talent acquisition and workforce optimization.

The solutions serve a diverse client base, including large enterprises, mid-sized companies, and public sector organizations across various industries, including technology, finance, and healthcare. Geographically, the company markets its products in North America, Europe, and parts of Asia, engaging with clients who are seeking data-driven insights to inform their human resources strategies. Revenue generation for the company is primarily structured around subscription-based models and assessment licenses, which allow clients to access a range of assessment tools tailored to their specific needs. Clients typically engage in contracts that enable them to utilize these tools over a defined period, facilitating ongoing assessments and continuous improvement in talent management practices.

The company’s flagship assessment products are integrated into broader human capital management strategies, with offerings that may include specialized leadership assessments and employee engagement surveys. Pricing plans are structured to accommodate various organizational sizes, providing scalable solutions that align with the complexity of the assessments provided. This transactional framework supports both business-to-business engagements and direct service provisions, fostering long-term partnerships with organizations committed to enhancing their workforce capabilities. The investment from December 2022 will support SHL Medical AG in expanding its production footprint to the US and Europe, as well as developing new drug delivery solution offerings.

The company is actively working on upcoming products designed to enhance healthcare delivery and improve patient outcomes. Plans for market expansion include targeting additional regions in North America and Europe by the end of 2024, capitalizing on the growing demand for innovative healthcare solutions.